Vincent D. Enright
About Vincent D. Enright
Vincent D. Enright (born 1943) is an Independent Director of The Gabelli Convertible and Income Securities Fund Inc. (GCV) since August 17, 2016. He is Chairman of GCV’s Audit Committee and designated as the Audit Committee Financial Expert, bringing prior CFO experience at KeySpan Corp. and formal executive education (Advanced Management Program at Harvard University) alongside a Bachelor’s degree from Fordham University . He oversees 17 portfolios across the Gabelli Fund Complex, indicating broad fund-governance exposure .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| KeySpan Corp. (energy public utility) | Senior Executive; Chief Financial Officer | 1994–1998 | Senior finance leadership; relevant for audit/financial oversight |
| Echo Therapeutics, Inc. (therapeutics & diagnostics) | Director | 2008–2014 | Chairman of Compensation Committee; member of Audit Committee |
| The LGL Group, Inc. (diversified manufacturing) | Director | 2011–2014 | Board service at public industrial company |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Echo Therapeutics, Inc. | Director; Chair of Compensation Committee; Audit Committee member | 2008–2014 | Therapeutics and diagnostics; governance committee leadership |
| The LGL Group, Inc. | Director | 2011–2014 | Diversified manufacturing |
Board Governance
- Committee assignments: Audit Committee (Chair; Financial Expert), ad hoc Pricing Committee, and both multi-fund ad hoc Compensation Committees (CCO comp and certain officers of closed-end funds) .
- Independence: Classified as an Independent Director under the 1940 Act; none of the Independent Directors (with possible exceptions described in proxy) nor their family members had interests in the Adviser or affiliates as of December 31, 2024 .
- Attendance: In FY ended September 30, 2024 the Board met 4 times; each Director attended ≥75% of Board and applicable committee meetings. The Audit Committee met 2 times in FY 2024 .
- Shareholder meetings: Directors were not expected to attend; none attended the May 13, 2024 annual meeting .
- Leadership structure: Independent Directors meet regularly in executive session; committees chaired by Independent Directors; Lead Independent Director is Anthonie C. van Ekris .
| Governance Metric | FY 2023 | FY 2024 |
|---|---|---|
| Board meetings held | 4 | 4 |
| Audit Committee meetings held | 2 | 2 |
| Director attendance threshold achieved | ≥75% | ≥75% |
Fixed Compensation
Directors are compensated in cash; fee schedule is standardized and role-based.
| Component | Amount | Notes |
|---|---|---|
| Annual retainer (Independent and certain Interested Directors) | $3,000 | Per director per year |
| Board meeting fee | $750 per meeting | Per director per meeting |
| Committee meeting fee | $500 per meeting | All committee members |
| Audit Committee Chair fee | $3,000 annual | Enright is Chair |
| Nominating Committee Chair fee | $2,000 annual | Not applicable to Enright |
| Lead Independent Director fee | $1,000 annual | Not applicable to Enright |
| Compensation (USD) | FY 2023 | FY 2024 |
|---|---|---|
| Aggregate compensation from GCV | $11,000 | $10,500 |
| Aggregate compensation from Fund Complex | $218,263 (17 portfolios) | $217,637 (17 portfolios) |
Performance Compensation
- No performance-based compensation, stock awards, options, or director equity grant programs are disclosed for directors. Director compensation is cash-based (retainers/meeting fees) with role premia; no TSR/EBITDA/revenue-linked metrics appear for directors in the proxy .
Other Directorships & Interlocks
| Company | Sector | Role | Tenure | Committee Roles | Potential Interlock/Conflict Notes |
|---|---|---|---|---|---|
| Echo Therapeutics, Inc. | Therapeutics & diagnostics | Director | 2008–2014 | Chair Compensation; Audit member | No current role; no disclosed GCV related-party transactions |
| The LGL Group, Inc. | Diversified manufacturing | Director | 2011–2014 | — | No current role; no disclosed GCV related-party transactions |
Expertise & Qualifications
- Financial oversight: Audit Committee Chair; Audit Committee Financial Expert designation (Reg S-K 407(d)(5)(ii)-(iii)) .
- Senior finance/operator background: CFO of KeySpan (public utility), relevant for controls, financial reporting, and risk oversight .
- Education: Bachelor’s degree from Fordham University; Advanced Management Program at Harvard University .
- Fund-complex breadth: Oversees 17 portfolios, indicating experience across closed-end/registered funds .
Equity Ownership
| Holding (as of 12/31/2024) | Amount | % Outstanding |
|---|---|---|
| GCV Common Stock | 0 shares | <1%* |
| GCV Preferred Stock | 0 shares | — |
| Dollar range in GCV | A (None) | — |
| Aggregate dollar range in Fund Complex | E (Over $100,000) | — |
*An asterisk indicates beneficial ownership constitutes less than 1% of shares outstanding .
Governance Assessment
- Strengths: Experienced CFO; chairs Audit Committee and serves as designated Financial Expert; consistent attendance; standardized cash compensation with transparent role-based fees; broad multi-fund governance experience .
- Alignment signals: Enright reported no GCV share ownership as of December 31, 2024, while reporting “Over $100,000” aggregate holdings across the Fund Complex; for GCV specifically, this implies limited direct “skin-in-the-game” alignment .
- Engagement: Audit Committee was active (two meetings in FY 2024) and issued required reports; Board held quarterly meetings. Directors did not attend the 2024 annual meeting (consistent with policy of not expecting attendance), which may modestly limit direct shareholder interaction .
- Conflicts/Related-party exposure: No related-party transactions disclosed for Enright; independence affirmed under the 1940 Act. Participation in multi-fund compensation committees is intra-complex governance, not a disclosed conflict with GCV stakeholders .
- RED FLAGS:
- No direct ownership of GCV shares (Dollar range “A – None”; 0 shares). This may weaken pay-for-performance alignment for GCV specifically .